Weekly Dose: aspirin, the pain and fever reliever that prevents heart attacks, strokes and maybe cancer Andrew Tonkin, Monash University Aspirin is, like ibuprofen and Voltaren (diclofenac), a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and reduce fever. What makes aspirin different from other NSAIDs is its ability to thin the blood, and it…Details
Researchers cite ASPREE to inform aspirin guidelines International researchers anticipate findings from the ASPREE study will help fill a knowledge gap that led to the exclusion of older people from recent US aspirin guidelines. Several articles in the Annals of Internal Medicine, which cited or discussed the ASPREE study, were published alongside the release of the US Preventive Services Task…Details
Leading US health authority releases aspirin recommendations to prevent cardiovascular disease and cancer in middle-aged The US Preventive Services Task Force (USPSTF) yesterday proposed that aspirin should be taken by more people to prevent cardiovascular disease (heart attack and stroke) as well as colon cancer – but only if you are aged between 50 and…Details
Popular ASPREE staff and nurses Sally and Gillian, were delighted to catch up with participants at study updates in Wangaratta on 25th February and Lavington (Albury) on 26th February this year. Associate Professor Robyn Woods, EO of ASPREE gave both presentations, accompanied by Dr Carlene Britt, who is the ASPREE Regional Manager. Pictured left is…Details
Thanks to the wonderful support from older members of the community, their families and GPs, ASPREE hit a number of new milestones as it strove towards the recruitment target this year. Highlights of the year include: • ASPREE reached the recruitment target of 19,000 participants across both countries in November 2014; 16,700 participants are Australian.…Details
Chief Investigator to the ASPREE Study, Professor Mark Nelson hosted the Hobart study update at the Menzies Institute for Medical Research today. We’d like to thank our participants and their guests and Jess Stewart, daughter of ASPREE’s Hobart team member, Kirby Donaldson for the pics from today’s event.
Wonderful to meet so many ASPREE participants and guests in Gippsland this month. We kicked off at the Traralgon Tennis Association rooms on 3rd December followed by a second presentation in Bairnsdale on 4th December. ASPREE Executive Officer, Assoc/Professor Robyn Woods gave the presentations, accompanied by Dr Carlene Britt, ASPREE’s Regional Manager. Local ASPREE study co-ordinators…Details
A letter from Principal Investigator, Prof John McNeil to 16,500 Australian ASPREE Participants and their GPs
To our ASPREE participants and co-investigating GPs, The ASPREE team sincerely thanks you for supporting the ASPREE study. Without your ongoing support for medical research, this significant trial would not be possible. For the next 3 years, ASPREE will be in the ‘observational’ stage until the trial concludes at the end of 2017. This 3 year…Details
Dr Sharyn Fitzgerald, ASPREE Regional Manager, visited her home town Wonthaggi at a study update today. Wonthaggi, a small hamlet in South Gippsland, has one of the highest participation rates in Australia, much to Sharyn’s immense pride. We would like to thank the Wonthaggi Club and the general community for their support for the ASPREE study.…Details
In terms of numbers, the biggest single study update so far this year belongs to Geelong, with more than 300 ASPREE participants and guests attending the event at Simonds Stadium (Kardinia Park) this month. A fantastic morning enjoyed by all.